| # | Title | Journal | Year | Citations |
|---|
| 1 | The forced swimming test as a model for core and component behavioral effects of antidepressant drugs | Behavioural Pharmacology | 1997 | 684 |
| 2 | A review of delay-discounting research with humans: relations to drug use and gambling | Behavioural Pharmacology | 2006 | 636 |
| 3 | The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior | Behavioural Pharmacology | 2007 | 592 |
| 4 | Tolerance and sensitization to the behavioral effects of drugs | Behavioural Pharmacology | 1993 | 421 |
| 5 | Animal models of ??anxiety??: where next? | Behavioural Pharmacology | 1997 | 403 |
| 6 | Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon | Behavioural Pharmacology | 2000 | 389 |
| 7 | SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats | Behavioural Pharmacology | 2002 | 387 |
| 8 | Neuroprotective and disease-modifying effects of the ketogenic diet | Behavioural Pharmacology | 2006 | 384 |
| 9 | The validity of animal models of predisposition to depression | Behavioural Pharmacology | 2002 | 374 |
| 10 | Genetics of dopamine receptors and drug addiction: a comprehensive review | Behavioural Pharmacology | 2009 | 350 |
| 11 | Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies | Behavioural Pharmacology | 2002 | 342 |
| 12 | The pharmacology and neural circuitry of sensitization to psychostimulants | Behavioural Pharmacology | 1993 | 326 |
| 13 | Individual reactivity to novelty predicts probability of amphetamine self-administration | Behavioural Pharmacology | 1990 | 256 |
| 14 | Windows of vulnerability to psychopathology and therapeutic strategy in the adolescent rodent model | Behavioural Pharmacology | 2004 | 227 |
| 15 | The role of hippocampus in anxiety: intracerebral infusion studies | Behavioural Pharmacology | 2007 | 218 |
| 16 | CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents | Behavioural Pharmacology | 2004 | 215 |
| 17 | Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice | Behavioural Pharmacology | 2000 | 210 |
| 18 | Tolerance and sensitization to the behavioral effects of drugs | Behavioural Pharmacology | 1993 | 206 |
| 19 | The complex role of serotonin and 5-HT receptors in chronic pain | Behavioural Pharmacology | 2011 | 204 |
| 20 | The psychobiology of comfort eating | Behavioural Pharmacology | 2012 | 204 |
| 21 | SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset | Behavioural Pharmacology | 1998 | 204 |
| 22 | Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal | Behavioural Pharmacology | 1995 | 199 |
| 23 | Impulsivity predicts individual susceptibility to high levels of alcohol self-administration | Behavioural Pharmacology | 1995 | 196 |
| 24 | The free-exploratory paradigm | Behavioural Pharmacology | 1993 | 193 |
| 25 | Phencyclidine-induced stereotyped behaviour and social isolation in rats | Behavioural Pharmacology | 1996 | 192 |
| 26 | AR-R 17779, an α7 nicotinic agonist, improves learning and memory in rats | Behavioural Pharmacology | 1999 | 192 |
| 27 | Antagonism of cocaine self-administration by selective dopamine D1 and D2 antagonists | Behavioural Pharmacology | 1990 | 191 |
| 28 | Endocannabinoids in the regulation of appetite and body weight | Behavioural Pharmacology | 2005 | 183 |
| 29 | Animal models for the negative symptoms of schizophrenia | Behavioural Pharmacology | 2000 | 178 |
| 30 | Using glutamate homeostasis as a target for treating addictive disorders | Behavioural Pharmacology | 2010 | 177 |
| 31 | Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice | Behavioural Pharmacology | 2003 | 176 |
| 32 | Investigating the behavioral and self-report constructs of impulsivity domains using principal component analysis | Behavioural Pharmacology | 2009 | 172 |
| 33 | Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders | Behavioural Pharmacology | 2003 | 170 |
| 34 | Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures | Behavioural Pharmacology | 1995 | 169 |
| 35 | Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? | Behavioural Pharmacology | 2005 | 169 |
| 36 | Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions | Behavioural Pharmacology | 2008 | 168 |
| 37 | Conditioned cued recovery of responding following prolonged withdrawal from self-administered cocaine in rats: an animal model of relapse | Behavioural Pharmacology | 1996 | 168 |
| 38 | Attentional and evaluative biases for smoking cues in nicotine dependence: component processes of biases in visual orienting | Behavioural Pharmacology | 2004 | 163 |
| 39 | Caffeine and the dopaminergic system | Behavioural Pharmacology | 2005 | 162 |
| 40 | Locomotor stimulant and discriminative stimulus effects of ‘bath salt’ cathinones | Behavioural Pharmacology | 2013 | 160 |
| 41 | Animal models with construct validity for schizophrenia | Behavioural Pharmacology | 1990 | 158 |
| 42 | Behavioural pharmacology and its contribution to the molecular basis of memory consolidation | Behavioural Pharmacology | 2000 | 158 |
| 43 | Preferential role of D3 dopamine autoreceptor in regulation of dopamine release but not synthesis in nucleus accumbens and dorsal striatum of freely moving rats | Behavioural Pharmacology | 1995 | 157 |
| 44 | The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats | Behavioural Pharmacology | 2003 | 155 |
| 45 | Emerging neurochemical concepts in the actions of ethanol at ligand-gated ion channels | Behavioural Pharmacology | 1994 | 153 |
| 46 | Stress-induced hyperlocomotion as a confounding factor in anxiety and depression models in mice | Behavioural Pharmacology | 2005 | 152 |
| 47 | Comparison of the phenotype of NK1R−/− mice with pharmacological blockade of the substance P (NK 1 ) receptor in assays for antidepressant and anxiolytic drugs | Behavioural Pharmacology | 2001 | 149 |
| 48 | The role of hippocampus in the pathophysiology of bipolar disorder | Behavioural Pharmacology | 2007 | 149 |
| 49 | Drug-induced neurobehavioral plasticity: the role of environmental context | Behavioural Pharmacology | 2004 | 148 |
| 50 | Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids | Behavioural Pharmacology | 2005 | 147 |
